Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes

ABSTRACT Infections from multidrug-resistant (MDR) bacteria lead to worse outcomes in immunocompromised patients. Eravacycline (ERV) is effective against MDR gram-negative and gram-positive bacteria, but its effects in immunocompromised populations remain unstudied. We aimed to evaluate clinical end...

Full description

Bibliographic Details

Published in:	Microbiology Spectrum
Main Authors:	Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Taylor Morrisette, Kyle C. Molina, Alaina DeKerlegand, Melanie Rae Schrack, S. Lena Kang-Birken, Athena L. V. Hobbs, Jazmin Agee, Nicholson B. Perkins, Mark Biagi, Michael Pierce, James Truong, Justin Andrade, Jeannette Bouchard, Tristan Gore, Madeline A. King, Benjamin M. Pullinger, Kimberly C. Claeys, Shelbye Herbin, Reese Cosimi, Serina Tart, Michael P. Veve, Bruce M. Jones, Leonor M. Rojas, Amy K. Feehan, Jing J. Zhao, Paige Witucki, Michael J. Rybak
Format:	Article
Language:	English
Published:	American Society for Microbiology 2025-10-01
Subjects:	eravacycline multidrug-resistant antimicrobial stewardship immunocompromised
Online Access:	https://journals.asm.org/doi/10.1128/spectrum.00565-25